ClinicalTrials.gg
CompletedNCT00508742Updated May 10, 2013Results posted

Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization

A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine and 7 valent pneumococcal conjugate vaccine in Pneumococcal Infections, sponsored by Pfizer. Completed at 5 sites in Israel. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-05-10.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,866
Allocation
Randomized
Ages
42 Days to 98 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.

Enrollment
4th of 44
1,866 · median 328
Started
2007
with 5 others
Phase 3
19 of 44
none open now
Registered
7th of 44
by date
Lead sponsor
16 of 44
Pfizer

Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 4th largest by enrollment, is one of 6 that started in 2007, is one of 19 in phase 3, and was the 7th registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →

About 13-valent pneumococcal vaccine

13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 42 Days to 98 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections as a file.
02

Study summary

This study is designed to assess the impact of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) on nasopharyngeal colonization with Streptococcus pneumoniae in healthy infants.

03

Conditions studied

  • Pneumococcal Infections

Keywords

  • Nasopharyngeal Colonization
  • Streptococcus pneumoniae
  • Healthy Infants
  • Vaccines
  • Pneumococcal Conjugate Vaccine
04

Who can participate

Ages eligible
42 Days to 98 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy infants aged 2 months (42-98 days) at time of enrolment.
  • Available for the entire study period and whose parent/legal guardian can be reached by telephone.

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with licensed or pneumococcal vaccine.
  • A previous anaphylactic reaction to any vaccine or vaccine-related component.
  • to vaccination with a pneumococcal conjugate vaccine.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,866 participants (actual)

Study arms

  • Experimental
    1

    13 valent pneumococcal conjugate vaccine

    Biological: 13-valent Pneumococcal Conjugate Vaccine

  • Active comparator
    2

    7 valent pneumococcal conjugate vaccine

    Biological: 7 valent pneumococcal conjugate vaccine

Interventions

  • 1 dose at 2, 4, 6 and 12 months of age

    Also known as: 13vPnC

  • Biological7 valent pneumococcal conjugate vaccine

    1 dose at 2, 4, 6 and 12 months of age

    Also known as: 7vPnC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a New Acquisition of Serotype 6A' (6A + 6C) or 19A Combined 1 Month After the Infant Series to 24 Months of Age

    A new acquisition was defined as the detection of a serotype (here 6A' \[6A + 6C\] or 19A), once a participant was fully vaccinated (one month after dose 3), that had not been detected previously in the baseline samples at 2, 4, 6 months of age.

    Time frame: Month 7 through Month 24

Secondary outcomes

  1. Percentage of Participants With Nasopharyngeal Cultures Testing Positive for 6A' (6A + 6C) or 19A Serotypes of Streptococcus Pneumoniae (S. Pneumoniae) at 7, 12, 13, 18 and 24 Months of Age

    Time frame: Month 7, 12, 13, 18, 24

07

Results

Posted Jul 13, 2012
Limitations and caveats
Study designated analysis of effect of 13vPnC on serotypes 6A+19A, changed prior to unblinding, to effect on 6A'+19A. Serotype 6A found to include serotype 6A isolates and isolates of newly identified serotype 6C. Serotype 6A assessed as 6A+6C (6A').

Participant flow

Period 1: Infant Series
Participant flow — Period 1: Infant Series
Milestone13vPnC7vPnC
Started932934
Vaccinated dose 1 (at 2 months of age)930933
Vaccinated dose 2 (at 4 months of age)904902
Vaccinated dose 3 (at 6 months of age)898892
Completed890889
Not completed4245
Withdrew: Adverse event54
Withdrew: Protocol violation10
Withdrew: Parent/legal guardian request3140
Withdrew: Physician decision10
Withdrew: Other41
Period 2: After Infant Series
Participant flow — Period 2: After Infant Series
Milestone13vPnC7vPnC
Started890889
Completed883878
Not completed711
Withdrew: Adverse event26
Withdrew: Lost to follow-up11
Withdrew: Protocol violation10
Withdrew: Parent/legal guardian request03
Withdrew: Failed to return10
Withdrew: Other21
Period 3: Toddler Dose
Participant flow — Period 3: Toddler Dose
Milestone13vPnC7vPnC
Started883878
Completed858863
Not completed2515
Withdrew: Adverse event10
Withdrew: Lost to follow-up23
Withdrew: Parent/legal guardian request178
Withdrew: Other54

Outcome measures

PrimaryPercentage of Participants With a New Acquisition of Serotype 6A' (6A + 6C) or 19A Combined 1 Month After the Infant Series to 24 Months of Age

A new acquisition was defined as the detection of a serotype (here 6A' \[6A + 6C\] or 19A), once a participant was fully vaccinated (one month after dose 3), that had not been detected previously in the baseline samples at 2, 4, 6 months of age.

Time frame:
Month 7 through Month 24
Reported as:
Number · percentage of participants
Percentage of Participants With a New Acquisition of Serotype 6A' (6A + 6C) or 19A Combined 1 Month After the Infant Series to 24 Months of Age
percentage of participants13vPnC7vPnC
Percentage of Participants With a New Acquisition of Serotype 6A' (6A + 6C) or 19A Combined 1 Month After the Infant Series to 24 Months of Age20.0 (17.4 to 22.8)36.0 (32.8 to 39.3)
Statistical analysis
  • 13vPnC vs 7vPnC · Rate ratio: 0.56 · 95% CI 0.47 to 0.65
SecondaryPercentage of Participants With Nasopharyngeal Cultures Testing Positive for 6A' (6A + 6C) or 19A Serotypes of Streptococcus Pneumoniae (S. Pneumoniae) at 7, 12, 13, 18 and 24 Months of Age
Time frame:
Month 7, 12, 13, 18, 24
Reported as:
Number · percentage of participants
Percentage of Participants With Nasopharyngeal Cultures Testing Positive for 6A' (6A + 6C) or 19A Serotypes of Streptococcus Pneumoniae (S. Pneumoniae) at 7, 12, 13, 18 and 24 Months of Age
percentage of participants13vPnC7vPnC
Month 7 (n= 881, 871)7.3 (5.6 to 9.2)10.9 (8.9 to 13.2)
Month 12 (n= 881, 873)8.1 (6.3 to 10.1)13.7 (11.5 to 16.2)
Month 13 (n= 871, 870)5.4 (4.0 to 7.1)13.6 (11.4 to 16.0)
Month 18 (n= 864, 864)7.1 (5.4 to 9.0)13.5 (11.3 to 16.0)
Month 24 (n= 855, 856)6.2 (4.7 to 8.0)10.7 (8.8 to 13.0)
Statistical analysis
  • 13vPnC vs 7vPnC · Odds ratio (or): 0.6 · 95% CI 0.5 to 0.9
  • 13vPnC vs 7vPnC · Odds ratio (or): 0.6 · 95% CI 0.4 to 0.7
  • 13vPnC vs 7vPnC · Odds ratio (or): 0.4 · 95% CI 0.3 to 0.5
  • 13vPnC vs 7vPnC · Odds ratio (or): 0.5 · 95% CI 0.4 to 0.7
  • 13vPnC vs 7vPnC · Odds ratio (or): 0.5 · 95% CI 0.4 to 0.8

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Infant Series 13vPnC—64/930 (6.9%)454/930 (48.8%)
Infant Series 7vPnC—57/933 (6.1%)433/933 (46.4%)
After Infant Series 13vPnC—48/929 (5.2%)290/929 (31.2%)
After Infant Series 7vPnC—64/931 (6.9%)324/931 (34.8%)
Toddler Dose 13vPnC—15/882 (1.7%)238/882 (27%)
Toddler Dose 7vPnC—23/875 (2.6%)240/875 (27.4%)
After Toddler Dose 13vPnC—91/882 (10.3%)462/882 (52.4%)
After Toddler Dose 7vPnC—73/875 (8.3%)455/875 (52%)
Most frequent serious events
Showing 10 of 145
Most frequent serious events
EventInfant Series 13vPnCInfant Series 7vPnCAfter Infant Series 13vPnCAfter Infant Series 7vPnCToddler Dose 13vPnCToddler Dose 7vPnCAfter Toddler Dose 13vPnCAfter Toddler Dose 7vPnC
GastroenteritisInfections and infestations11/9308/93312/92913/9313/8824/87513/88214/875
VomitingGastrointestinal disorders2/9305/9332/9290/9310/8824/87514/8827/875
Otitis mediaInfections and infestations3/9305/9339/92910/9311/8823/87513/88211/875
PyrexiaGeneral disorders8/9304/9336/9294/9310/8824/87511/88210/875
BronchiolitisInfections and infestations10/9308/9333/9294/9310/8820/8751/8821/875
PneumoniaInfections and infestations2/9301/9335/9297/9310/8821/8759/8825/875
Febrile convulsionNervous system disorders1/9302/9333/9295/9311/8821/8757/8828/875
DehydrationMetabolism and nutrition disorders1/9301/9331/9290/9310/8822/8758/8826/875
AsthmaRespiratory, thoracic and mediastinal disorders2/9300/9333/9291/9311/8822/8757/8825/875
Lower respiratory tract infectionInfections and infestations1/9304/9335/9294/9310/8821/8753/8821/875
Most frequent other events
Showing 10 of 125
Most frequent other events
EventInfant Series 13vPnCInfant Series 7vPnCAfter Infant Series 13vPnCAfter Infant Series 7vPnCToddler Dose 13vPnCToddler Dose 7vPnCAfter Toddler Dose 13vPnCAfter Toddler Dose 7vPnC
Otitis mediaInfections and infestations165/930137/933176/929195/93193/88292/875267/882246/875
PyrexiaGeneral disorders216/930194/93332/92937/93190/88289/87564/88268/875
PharyngitisInvestigations12/93024/93335/92932/93134/88227/875112/882114/875
RestlessnessPsychiatric disorders98/93089/9330/9290/93111/88211/8751/8820/875
PneumoniaInfections and infestations16/93014/93321/92925/9317/88213/87557/88258/875
Upper respiratory tract infectionInfections and infestations13/9305/93312/92915/9312/88211/87537/88243/875
DiarrhoeaGastrointestinal disorders16/9309/93313/9298/9314/8827/87525/88234/875
CoughRespiratory, thoracic and mediastinal disorders11/9304/9338/92910/9314/8821/87531/88220/875
LeukocytosisBlood and lymphatic system disorders6/9309/93313/92917/9314/8824/87515/88215/875
Urinary tract infectionInfections and infestations11/93016/93310/9295/9312/8823/87510/8826/875

Baseline characteristics

Age Continuous
Age Continuous(years)13vPnC7vPnCTotal
Mean2.2 ± 0.32.2 ± 0.32.2 ± 0.3
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC7vPnCTotal
Female474471945
Male458463921
08

Study locations

5 sites
  • Pfizer Investigational Sites (7)
    Beer-Sheva, 84101, Israel
  • Pfizer Investigational Site
    Ksaife, Israel
  • Pfizer Investigational Site
    Rahat A, Israel
  • Pfizer Investigational Site
    Rahat, Israel
  • Pfizer Investigational Site
    Segev Shalom, Israel
09

References and documents

Publications

  • Dagan R, Jiang Q, Juergens C, Trammel J, Gruber WC, Scott DA. Carrier-Induced Hyporesponsiveness to Pneumococcal Conjugate Vaccines: Unraveling the Influence of Serotypes, Timing, and Previous Vaccine Dose. Clin Infect Dis. 2021 Feb 1;72(3):448-454. doi: 10.1093/cid/ciaa083. PubMed 31995183 ↗
  • Dagan R, Juergens C, Trammel J, Patterson S, Greenberg D, Givon-Lavi N, Porat N, Gruber WC, Scott DA. PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children. Vaccine. 2017 Feb 7;35(6):945-950. doi: 10.1016/j.vaccine.2016.12.052. Epub 2017 Jan 11. PubMed 28087146 ↗
  • Dagan R, Juergens C, Trammel J, Patterson S, Greenberg D, Givon-Lavi N, Porat N, Gruber WC, Scott DA. Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration. Vaccine. 2016 Aug 5;34(36):4313-20. doi: 10.1016/j.vaccine.2016.06.075. Epub 2016 Jul 12. PubMed 27422342 ↗
  • Dagan R, Juergens C, Trammel J, Patterson S, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA. Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae. J Infect Dis. 2015 Apr 1;211(7):1144-53. doi: 10.1093/infdis/jiu576. Epub 2014 Oct 29. PubMed 25355940 ↗
  • Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis. 2013 Oct;57(7):952-62. doi: 10.1093/cid/cit428. Epub 2013 Jun 26. PubMed 23804191 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2007
First posted
Jul 30, 2007
Start
Dec 2007
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Jul 13, 2012
Last update
May 10, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00508742
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 30, 2007
Start date
Dec 2007
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Jul 13, 2012
Last update
May 10, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion